Dr LUI Tak Wai, David

Dr David Lui

Clinical Assistant Professor

  • MBBS (Hons) (HK); MRCP (UK); FHKCP; FHKAM (Medicine)
Biography
Dr David Lui obtained his MBBS degree with Honours from the University of Hong Kong in 2012 and obtained his MRCP (UK) in 2015. He completed his specialty training in Endocrinology, Diabetes and Metabolism in 2019 and Advanced Internal Medicine in 2020 at the Queen Mary Hospital. He joined the Department of Medicine, the University of Hong Kong, as a Clinical Assistant Professor since March 2021.

Dr Lui’s research interests include diabetic bone disease, and endocrine complications of cancer treatments and infections. Supported by the Hong Kong Society of Endocrinology, Metabolism and Reproduction and the Training and Research Assistance Scheme of the Queen Mary Hospital Charitable Trust, he studied the role of biomarkers in the bone health in type 2 diabetes. Later he went on to study the epidemiological aspect of fractures in diabetes using a territory-wide electronic health database. Amidst the COVID-19 pandemic, he has established a cohort of COVID-19 patients for the ongoing evaluation of endocrine dysfunction associated with COVID-19. His publication titled ‘Thyroid Dysfunction in Relation to Immune Profile, Disease Status and Outcome in 191 Patients with COVID-19’ has been listed among the Highly Cited Articles in the Journal of Clinical Endocrinology & Metabolism. He has published over 30 peer-reviewed articles in international journals including Diabetes Care, International Journal of Epidemiology and the Journal of Clinical Endocrinology & Metabolism. In recognition of his research work, he has been awarded both locally and internationally, including the Distinguished Research Paper Award for Young Investigators from the Hong Kong College of Physicians (2021) and the Rising Star Award in the International Congress of Diabetes and Metabolism (2021).

Research Profile
  • COVID-19 and Endocrinology
  • Osteoporosis and Fragility Fractures
  • Diabetic Bone Disease
  • Endocrine Complications of Cancer Treatments

Selected publications

    COVID-19 and Thyroid

    • Lui DTW, Lee CH, Chow WS, Lee ACH, Tam AR, Fong CHY, Law CY, Leung EKH, To KKW, Tan KCB, Woo YC, Lam CW, Hung IFN, Lam KSL. Thyroid Dysfunction in Relation to Immune Profile, Disease Status and Outcome in 191 Patients with COVID-19. J Clin Endocrinol Metab. 2021 Jan 23;106(2):e926-e935. (selected into JCEM Highly Cited Articles)
    • Lui DTW, Lee CH, Chow WS, Lee ACH, Tam AR, Fong CHY, Law CY, Leung EKH, To KKW, Tan KCB, Woo YC, Lam CW, Hung IFN, Lam KSL. Role of Non-Thyroidal Illness Syndrome in Predicting Adverse Outcomes in COVID-19 Patients Predominantly of Mild to Moderate Severity. Clin Endocrinol (Oxf). 2021 Sep;95(3):469-477.
    • Lui DTW, Lee CH, Lam KSL. Letter to the Editor: ‘Euthyroid sick syndrome as an early surrogate marker of poor outcome in mild SARSCoV2 disease prognostic significance of non-thyroidal illness syndrome in the whole spectrum of COVID-19 severity. Journal of Endocrinological Investigation. 2022 Jan 13;1-2. doi: 10.1007/s40618-021-01732-z.
    • Lui DTW, Lee CH, Chow WS, Lee ACH, Tam AR, Pang P, Ho TY, Cheung CYY, Fong CHY, Law CY, To KKW, Lam CW, Tan KCB, Woo YC, Hung IFN, Lam KSL. The independent association of TSH and free triiodothyronine levels with lymphocyte counts among COVID-19 patients. Front Endocrinol (Lausanne). 2022. (in press)
    • Lui DTW, Hung IFN, Lee CH, Lee ACH, Tam AR, Pang P, Ho TY, Cheung CYY, Fong CHY, Law CY, To KKW, Lam CW, Chow WS, Woo YC, Lam KSL, Tan KCB. The impact of interferon beta-1b therapy on thyroid function and autoimmunity among COVID-19 survivors. Front Endocrinol (Lausanne). 2021 Sep 30;12:746602.
    • Lui DTW*, Fung MMH*, Chiu KWH, Lee CH, Chow WS, Lee ACH, Tam AR, Pang P, Ho TY, Wong WW, Lee CYY, Fong CHY, Loong CHN, Law CY, To KKW, Lam CW, Tan KCB, Woo YC, Hung IFN, Lam KSL, Lang BHH. Higher SARS-CoV-2 Viral Loads Correlated with Smaller Thyroid Volumes on Ultrasound among Male COVID-19 Survivors. Endocrine. 2021 Nov;74(2):205-214. (*co-first author)
    • Lui DTW, Lee CH, Chow WS, Lee ACH, Tam AR, Pang P, Ho TY, Fong CHY, Law CY, Leung EKH, To KKW, Tan KCB, Woo YC, Lam CW, Hung IFN, Lam KSL. Long COVID in patients with mild to moderate disease: do thyroid function and autoimmunity play a role? Endocr Pract. 2021 Sep;27(9):894-902.
    • Lui DTW, Lee CH, Chow WS, Lee ACH, Tam AR, Fong CHY, Law CY, Leung EKH, To KKW, Tan KCB, Woo YC, Lam CW, Hung IFN, Lam KSL. Insights from prospective follow-up of thyroid function and autoimmunity among COVID-19 survivors. Endocrinol Metab (Seoul). 2021 Jun;36(3):582-589.
    • Lui DTW, Lee KK, Lee CH, Lee ACH, Hung IFN, Tan KCB. Development of Graves’ disease after SARS-CoV-2 mRNA vaccination: a case report and literature review. Front Public Health. 2021 Nov 23;9:778964.

     

    COVID-19 and Diabetes

    • Wong CKH*, Lui DTW*, Lui AYC*, Kwok ACY, Low MCH, Lau KTK, Au ICH, Xiong X, Chung MSH, Lau EHY, Cowling BJ. Metformin use in relation to clinical outcomes and hyperinflammatory syndrome among COVID-19 patients with type 2 diabetes: a propensity score analysis of a territory-wide cohort. Front Endocrinol (Lausanne). 2022. (in press) (*co-first author)
    • Wong CKH*, Lui DTW*, Lui AYC*, Kwok ACY, Low MCH, Lau KTK, Au ICH, Xiong X, Chung MSH, Lau EHY, Cowling BJ. Use of DPP4i reduced odds of clinical deterioration and hyperinflammatory syndrome in COVID-19 patients with type 2 diabetes: propensity score analysis of a territory-wide cohort in Hong Kong. Diabetes Metab. 2021 Dec 1;48(1):101307. (*co-first author)
    • Lui DTW, Tan KCB. Is metformin a miracle or a menace in COVID-19 patients with type 2 diabetes? J Diabetes Investig. 2021 Apr;12(4):479-481.
    • Lui DTW, Lee CH, Chow WS, Fong CHY, Woo YC, Lam KSL, Tan KCB. A territory‐wide study on the impact of COVID‐19 on diabetes‐related acute care. J Diabetes Investig. 2020 Sep;11(5):1303-1306.
    • Lui DTW, Lee CH, Tan KCB. One year into the clash of pandemics of diabetes and COVID-19: lessons learnt and future perspectives. J Diabetes Investig. 2022 Jan;13(1):19-21.

     

    Osteoporosis and Fragility Fractures

    • Lui DTW, Lee CH, Chan YH, Chow WS, Fong CHY, Siu DCW, Tse HF, Woo YC, Lam KSL. HbA1c variability, in addition to mean HbA1c, predicts incident hip fractures in Chinese people with type 2 diabetes. Osteoporos Int. 2020 Oct;31(10):1955-1964.
    • Lui DTW, Lee CH, Chau VWK, Fong CHY, Yeung KMY, Lam JKY, Lee ACH, Chow WS, Tan KCB, Woo YC, Lam KSL. Potential role of fibroblast growth factor 21 in the deterioration of bone quality in impaired glucose tolerance. J Endocrinol Invest. 2021 Mar;44(3):523-530.
    • Lui DTW*, Fung MMH*, Lee CH, Fong CHY, Woo YC, Lang BHH. A territory-wide assessment of the incidence of persistent hypoparathyroidism following elective thyroid surgery and its impact on new fracture risk over time. Surgery. 2021 Nov;170(5):1369-1375. (*co-first author)
    • Lui DTW*, Fung MMH*, Lee CH, Fong CHY, Loong CHN, Lam AHK, Tan KCB, Woo YC, Lang BHH. The potential role of preoperative trabecular bone score in predicting changes in bone mineral density after parathyroidectomy. World J Surg. 2021 Feb;45(2):522-530. (*co-first author)

     

    Lipidology

    • Lui DTW, Cheung CL, Lee ACH, Wong Y, Shiu SWM, Tan KCB. Carbamylated HDL and mortality outcomes in type 2 diabetes. Diabetes Care. 2021 Mar;44(3):804-809.
    • Lui DTW, Lee ACH, Tan KCB. Management of familial hypercholesterolemia: current status and future perspectives. Journal of the Endocrine Society. 2020 Aug 21;5(1):bvaa122. (Selected into Endocrine Society Thematic Issue on Lipids and Adipocytes 2021)
    • Lui DTW, Tan KCB. Low-density lipoprotein cholesterol and stroke - how low should we go? J Diabetes Investig. 2020 Nov;11(6):1379-1381.
    • Lui DTW, Lee ACH, Yap DYH, Chan GSW, Tan KCB. A young Chinese man with nephrotic syndrome due to lipoprotein glomerulopathy. J Clin Lipidol. 2019 Mar - Apr;13(2):251-253.

     

    Immunotherapy-related endocrinopathies

    • Lui DTW, Lee CH, Tang V, Fong CHY, Lee ACH, Chiu JWY, Leung RCY, Kwok GGW, Li BCW, Cheung TT, Woo YC, Lam KSL, Yau T. Thyroid immune-related adverse events in cancer patients treated with anti-PD1/anti-CTLA4 immune-checkpoint inhibitor combination: clinical course and outcomes. Endocr Pract. 2021 Sep;27(9):886-893.

Awards
  1. Best Abstract in Clinical Medicine (Poster), 26th Medical Research Conference (2022)
  2. Best Poster Exhibition Award in 9th Seoul International Congress of Endocrinology and Metabolism (2021)
  3. International Congress of Diabetes and Metabolism Rising Star Award (2021)
  4. Distinguished Research Paper Award for Young Investigators, Hong Kong College of Physicians (2021)
  5. Best Abstract in Clinical Medicine (Oral), 26th Medical Research Conference (2021)
  6. Best Poster Presentation (Clinical Session), HKSEMR Annual Scientific Meeting (2020)
  7. International Non-Fellow Physician AACE Travel Grant Award, AACE 29th Annual Scientific & Clinical Congress (2020)
  8. Best Oral Presentation (Clinical Session), HKSEMR Annual Scientific Meeting (2019)
  9. Poster Award, Asia Islet Biology & Incretin Symposium (2019)
  10. Best Abstract in Clinical Medicine (Poster), 24th Medical Research Conference (2019)
  11. Best Oral Presentation (Clinical Session), HKSEMR Annual Scientific Meeting (2018)